Democrats escalate probe of Trump admin drug pricing deals

Democrats are pushing for pharmaceutical companies to reveal the specifics of their "most favored nation" deals with the Trump administration, aiming to scrutinize the pricing strategies that could affect drug affordability and access. This move by Congressional Democrats underscores their commitment to healthcare policy oversight as they gear up to lead in the upcoming session. The demand for transparency in these agreements is crucial as it could highlight potential conflicts of interest or unfair practices that influence drug pricing and public health outcomes.